Golden Matrix Group, Inc. (GMGI) Dividend History

Golden Matrix Group, Inc. (GMGI) is a technology company specializing in online gaming and casino platform solutions. It develops and operates gaming software and platforms for the online gambling industry, providing a range of casino games, sports betting, and related services to operators worldwide. The company focuses on delivering innovative gaming content and scalable technology to support the growth of digital wagering.

3651 Lindell Road, Ste D131, Las Vegas, NV, 89103
Phone: 702-318-7548
Website: https://www.goldenmatrix.com

Dividend History

Golden Matrix Group, Inc. currently does not pay dividends

Company News

  • Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (GMGI), has signed a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta.

    GlobeNewswire Inc.
  • U.S. stocks turned higher midway through trading, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.48% to 32,026.53 while the NASDAQ rose 1.72% to 11,630.84. The S&P 500, also fell, dropping, 1.08% to 3,933.96. Check This Out: Top 5 Tech Stocks Which You'll Regret Missing This Quarter   Leading and Lagging Sectors Communication services shares rose by 0.9% on Thursday. Meanwhile, top gainers in the sector included Telesat Corporation (NASDAQ: TSAT), up 4%, and Golden Matrix Group, Inc. (NASDAQ: GMGI), up 4%. In trading on Thursday, energy shares tumbled by 2%.   Top Headline US export prices climbed by 0.2% from a month ago in February, while import prices declined 0.1%.   Equities Trading UP PureCycle Technologies, Inc. (NASDAQ: PCT) shares shot up 29% to $6.16 after the company provided a Q4 2022 update. Shares of UiPath Inc. (NYSE: PATH) got a boost, shooting 17% to $17.06 after the company reported better-than-expected Q4 results and issued strong revenue guidance. Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares were also up, gaining 42% to $2.5420 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.   Equities Trading ...

    Benzinga
    Featured Companies: ESPR LIPO LPSN PATH PCT TSAT
Page data last updated 08/19/2025 00:48:51 UTC